default author photo

Hai-Yan Tu

Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute

SCHOLARLY PAPERS

2

DOWNLOADS

69

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

A Unique Population of Lipid-Associated Macrophages in Cerebrospinal Fluid: Implications for NSCLC Leptomeningeal Metastases Development and Osimertinib Resistance

Number of pages: 80 Posted: 13 Sep 2023
Yangsi Li, Wen-Pu Lai, Kai Yin, Mei-Mei Zheng, Hai-Yan Tu, Wei-Bang Guo, Liang Li, Shou-Heng Lin, Zhen Wang, Lu Zeng, Ben-Yuan Jiang, Zhi-Hong Chen, Qing Zhou, Xuchao Zhang, Jin-Ji Yang, Wen-Zhao Zhong, Xue-Ning Yang, Bin-Chao Wang, Yi Pan, Hua-Jun Chen, Fa-Man Xiao, Hao Sun, Yue-Li Sun, Xiao-Yan Bai, E-E Ke, Jia-Xin Lin, Si-Yang Maggie Liu, Yangqiu Li, Oscar Junhong Luo and Yi-Long Wu
South China University of Technology - School of Medicine, Jinan University - Department of Hematology, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Southern Medical University - Medical Research Institute, China-New Zealand Joint Laboratory on Biomedicine and Health, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Southern Medical University, Jinan University - Department of Hematology, Jinan University - Department of System Biomedical Sciences and Southern Medical University
Downloads 41 (1,170,409)

Abstract:

Loading...

Leptomeningeal metastases, Osimertinib resistance, macrophage, Midkine, Cerebrospinal fluid

2.

A Patient-Centric, Open-Label, Multicenter, Phase Ii Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients with Locally Advanced or Metastatic Alk-Positive Non-Small Cell Lung Cancer (Ctong2203)

Number of pages: 18 Posted: 05 Apr 2025
Jia-Xin Lin, Qing Zhou, Hong-Hong Yan, Anwen Liu, Guo-Wu Wu, Qian Chu, Yingying Du, Jiuwei Cui, Ying Cheng, Y. Yang, Haipeng Xu, Hai-Yan Tu, Yi-Long Wu and Si-Yang Maggie Liu
affiliation not provided to SSRN, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, affiliation not provided to SSRN, Nanchang University - Department of Medical Oncology, affiliation not provided to SSRN, Huazhong University of Science and Technology - Department of Oncology, Anhui Medical University - Department of Oncology, Jilin University (JLU) - Cancer Center, Jilin Cancer Hospital - Department of Oncology, Southwest Jiaotong University, Fujian Medical University - Department of Thoracic Oncology, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Southern Medical University and Southern Medical University
Downloads 28 (1,359,097)

Abstract:

Loading...

non-small cell lung cancer, lorlatinib, ALK-positive, first-line treatment, Patient-centric trial